 Q BioMed Inc OTCQB:QBIO revealed that it has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the companys metastatic bone pain drug Strontium89. The New York-based biotech said that under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait and Pakistan. 